This study was conducted to investigate the pharmacological activity of cocoa polyphenols (CPs) on visceral obesity markers and the possible mechanisms. In this study, Sprague-Dawley (SD) rats were fed either a low-fat diet (LFD) or a high-fat diet (HFD). After 12 wk of diet intervention, only one group of HFD rats (n ¼ 10/ group) were treated at a dose of 600 mg/kg bw/day CPs (HFD þ CPs) for 4 wk. The gene and protein expression levels of phosphorylation of AMPK-activated protein kinase a/b (AMPK a/b) were measured using real time-PCR and Western blotting. The mRNA expression of lipogenic key enzymes (Acaca, Fasn, Mcat, and Scd-1), and b-oxidation key enzymes (CPT1, Prkaa1, Acox1) were investigated. In addition, the upstream transcription factors (PPARa, PPARg, C/EBPa, and SREBP-1c) were also examined. In accordance with these findings, CPs treatment improved visceral adiposity, adipocytes hypertrophy, and liver steatosis. AMPactivated protein kinase a/b (AMPK a/b) phosphorylation in liver and adipose tissue of HFD þ CPs-treated rats was activated compared with HFD-fed rats. The expression of lipogensis related-genes was decreased, while expression levels of b-oxidation-related genes were increased compared with HFD-fed rats. Together, these data partially unravel the ameliorative effects of CPs treatment on visceral obesity markers by inhibiting lipogenesis and promoting b-oxidation related-genes through activation of the AMPK pathway.
Introduction
Visceral obesity is a growing global disease that usually develops from excessive fat storage and adiposity of mesenteric adipose tissue. Because obesity is accounted as a major risk factor for most metabolic diseases, including dyslipidemia, type 2 diabetes, hypertension, and cardiovascular disease, many studies have been conducted to disclose the main components in energy homeostasis, which is critical to develop therapeutic agents for obesity and obesityassociated metabolic diseases [1] [2] [3] . A group of transcription factors such as peroxisome proliferator-activated receptor g
